These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2578328)

  • 1. The roles of two peritoneal T-lymphocyte populations in the in vivo rejection of methylcolanthrene-induced sarcoma.
    Kadhim SA; Rees RC; Barrington-Leigh J
    Cell Immunol; 1985 Jan; 90(1):234-41. PubMed ID: 2578328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypes associated with tumor rejection mediated by cyclophosphamide and syngeneic tumor-sensitized T lymphocytes: potential mechanisms of action.
    Evans R
    Int J Cancer; 1984 Mar; 33(3):381-8. PubMed ID: 6607893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of tumor specific delayed type hypersensitivity reaction and tumor protection to SV40-induced mKSA fibrosarcoma.
    Kadhim S; Barrington-Leigh J
    Cancer Immunol Immunother; 1986; 21(1):39-44. PubMed ID: 3002606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common transplantation antigens on methylcholanthrene-induced murine sarcomas detected by three assays of tumor rejection.
    Leffell MS; Coggin JH
    Cancer Res; 1977 Nov; 37(11):4112-9. PubMed ID: 908044
    [No Abstract]   [Full Text] [Related]  

  • 5. Cross-reactive cellular and humoral immunity to carcinogen-induced chicken fibrosarcomas. I. Protective cross-immunity between transplantable tumor lines.
    Edelman AS; Xue B; Sanchez P; Thorbecke GJ
    J Immunol; 1985 Sep; 135(3):2206-12. PubMed ID: 3926898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-mediated suppression of tumor immunity has a non-specific component. I. Evidence from transplantation tests.
    Hellström KE; Hellström I
    Int J Cancer; 1981; 27(4):481-5. PubMed ID: 6168591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of H-2 antigens in the host response to methylcholanthrene-induced tumors.
    Ahrlund-Richter L; Klein E; Merino F
    Immunogenetics; 1982 Jan; 15(1):53-62. PubMed ID: 6979509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in tumor-specific antigen expression during passage in vitro and in vivo of newly derived methylcholanthrene-induced sarcomas of BALB/C mice.
    Law LW
    Int J Cancer; 1980 Feb; 25(2):251-9. PubMed ID: 6156130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
    J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell surface antigens of murine leukemias induced by radiation leukemia virus. Recognition of individually distinct cell surface antigens by cytotoxic T cells on leukemias expressing crossreactive transplantation antigens.
    Morishita H; Shiku H; Horibe K; Obata Y; Stockert E; Oettgen HF; Old LJ; Yamada K
    J Exp Med; 1986 Feb; 163(2):452-7. PubMed ID: 3003228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of T-cell lines with inhibitory or stimulatory activity against syngeneic tumors in vivo. A preliminary report.
    Mulé JJ; Forstrom JW; George E; Hellström I; Hellström KE
    Int J Cancer; 1981 Nov; 28(5):611-4. PubMed ID: 6796530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotype analyses and cellular mechanisms of the pre-effector T-lymphocyte response to a progressive syngeneic murine sarcoma.
    Sakai K; Chang AE; Shu SY
    Cancer Res; 1990 Jul; 50(14):4371-6. PubMed ID: 2114215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.
    Chou T; Shu S
    J Immunol; 1987 Sep; 139(6):2103-9. PubMed ID: 2957448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effector phenotype and immunologic specificity of T-cell-mediated adoptive therapy for a murine tumor that lacks intrinsic immunogenicity.
    Sakai K; Chang AE; Shu S
    Cell Immunol; 1990 Aug; 129(1):241-55. PubMed ID: 2364440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-reacting antigens in chemically induced sarcomas are fetal determinants.
    Parker GA; Rosenberg SA
    J Immunol; 1977 May; 118(5):1590-4. PubMed ID: 67142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-mediated reactivity to antigens shared by Moloney-virus-induced lymphomas (LSTRA) and certain 3-methylcholanthrene-induced mouse sarcomas.
    Hellström I; Hellström KE; Zeidman L; Bernstein ID; Brown JP
    Int J Cancer; 1979 Apr; 23(4):555-64. PubMed ID: 86527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Lyt phenotype of the T cells responsible for in vivo tumor rejection in syngeneic mice.
    Ozawa H; Iwaguchi T; Kataoka T
    Cancer Immunol Immunother; 1986; 23(1):73-7. PubMed ID: 3533258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of the A/Ph.MC.S1 tumor graft rejection in syngeneic mice.
    Zákány J; Jánossy T; Németh P; Chihara G; Fachet J; Petri G
    Gan; 1983 Oct; 74(5):712-22. PubMed ID: 6357932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Lyt phenotype of the T cells in an antitumor adoptive transfer differs for "parent to F1" and "parent to parent" combinations.
    Ahrlund-Richter L; Wikström AC; Ramqvist T; Klein E
    Cell Immunol; 1984 Jul; 86(2):575-82. PubMed ID: 6610486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-reacting tumor associated transplantation antigen on primary 3-methylcholanthrene-induced BALB/c sarcomas.
    Coggin JH
    Mol Biother; 1989; 1(4):223-8. PubMed ID: 2818874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.